Literature DB >> 29064904

Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy.

Henry M Kuerer1, Savitri Krishnamurthy, Gaiane M Rauch, Wei T Yang, Benjamin D Smith, Vicente Valero.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29064904      PMCID： PMC6056325          DOI： 10.1097/SLA.0000000000002573

Source DB:  PubMed          Journal:  Ann Surg        ISSN： 0003-4932            Impact factor:   12.969


× No keyword cloud information.
  3 in total

1.  Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?

Authors:  Joerg Heil; Benedikt Schaefgen; Peter Sinn; Hannah Richter; Aba Harcos; Christina Gomez; Anne Stieber; André Hennigs; Geraldine Rauch; Florian Schuetz; Christof Sohn; Andreas Schneeweiss; Michael Golatta
Journal:  Eur J Cancer       Date:  2016-11-04       Impact factor: 9.162

2.  A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

Authors:  Henry M Kuerer; Gaiane M Rauch; Savitri Krishnamurthy; Beatriz E Adrada; Abigail S Caudle; Sarah M DeSnyder; Dalliah M Black; Lumarie Santiago; Brian P Hobbs; Anthony Lucci; Michael Gilcrease; Rosa F Hwang; Rosalind P Candelaria; Mariana Chavez-MacGregor; Benjamin D Smith; Elsa Arribas; Tanya Moseley; Mediget Teshome; Makesha V Miggins; Vicente Valero; Kelly K Hunt; Wei T Yang
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

3.  Nonoperative Management for Invasive Breast Cancer After Neoadjuvant Systemic Therapy: Conceptual Basis and Fundamental International Feasibility Clinical Trials.

Authors:  Henry M Kuerer; Marie-Jeanne T F D Vrancken Peeters; Daniel W Rea; Mark Basik; Jennifer De Los Santos; Joerg Heil
Journal:  Ann Surg Oncol       Date:  2017-08-01       Impact factor: 5.344
  3 in total
  2 in total

1.  Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.

Authors:  Aman U Buzdar; Vera J Suman; Funda Meric-Bernstam; Ann Marilyn Leitch; Matthew J Ellis; Judy C Boughey; Gary W Unzeitig; Melanie E Royce; Kelly K Hunt
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

Review 2.  Innovative Standards in Surgery of the Breast after Neoadjuvant Systemic Therapy.

Authors:  Tal Hadar; Michael Koretz; Mahmood Nawass; Tanir M Allweis
Journal:  Breast Care (Basel)       Date:  2021-11-02       Impact factor: 2.860
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.